Thyroid cancer

Nova Scotia Health Partners with Medable for Decentralized Clinical Trial Technology to Improve Oncology Patient Access

Retrieved on: 
Thursday, February 2, 2023

Medable Inc. , the leading technology platform for clinical trials, announced that its decentralized clinical trial (DCT) platform was selected by the Nova Scotia Health Innovation Hub to increase the accessibility of oncology care for remote patients in rural Nova Scotia, with the long-term aim to improve patient access and trial diversity across Canada.

Key Points: 
  • Medable Inc. , the leading technology platform for clinical trials, announced that its decentralized clinical trial (DCT) platform was selected by the Nova Scotia Health Innovation Hub to increase the accessibility of oncology care for remote patients in rural Nova Scotia, with the long-term aim to improve patient access and trial diversity across Canada.
  • View the full release here: https://www.businesswire.com/news/home/20230202005388/en/
    For oncology patients living in rural parts of Nova Scotia, accessing follow-up care can be challenging, especially when it requires lengthy travel time and costs.
  • That’s why Nova Scotia Health is partnering with Medable on a two-year pilot study, launched in January 2023, to improve access to clinical trials.
  • Learn more about Medable’s partnership with Nova Scotia Health and other leaders at the 14th Annual SCOPE Conference (February 6-9, 2023) in Orlando, FL – booth #613.

Tampa Thyroid Surgeon Selected as Finalist for Prestigious Tampa Bay Business Women Awards

Retrieved on: 
Thursday, February 2, 2023

TAMPA, Fla., Feb. 2, 2023 /PRNewswire/ -- Dr. Rashmi Roy, senior thyroid surgeon at the Clayman Thyroid Center operating at the Hospital for Endocrine Surgery, has been selected as a finalist for Tampa Bay Business & Wealth's Business Women Awards by an outside panel of judges.

Key Points: 
  • TAMPA, Fla., Feb. 2, 2023 /PRNewswire/ -- Dr. Rashmi Roy, senior thyroid surgeon at the Clayman Thyroid Center operating at the Hospital for Endocrine Surgery, has been selected as a finalist for Tampa Bay Business & Wealth's Business Women Awards by an outside panel of judges.
  • The Tampa Bay Business Women Awards is a unique awards program, created by Tampa Bay Business & Wealth Magazine, to recognize distinguished women leaders whose dedication to their industries and communities deserves particular recognition.
  • The Clayman Thyroid Center is a full-service thyroid surgery practice, performing more than 2,000 thyroid operations annually.
  • It specializes in all types of thyroid surgery, including scarless robotic thyroid surgery.

NiKang Therapeutics Appoints Anne E. Borgman, M.D., to Board of Directors

Retrieved on: 
Wednesday, January 18, 2023

NiKang Therapeutics Inc. (“NiKang”), a clinical stage biotech company focused on developing innovative small molecule oncology medicines to help patients with unmet medical needs, today announced that Dr. Anne Borgman has been appointed to the company’s Board of Directors.

Key Points: 
  • NiKang Therapeutics Inc. (“NiKang”), a clinical stage biotech company focused on developing innovative small molecule oncology medicines to help patients with unmet medical needs, today announced that Dr. Anne Borgman has been appointed to the company’s Board of Directors.
  • Dr. Borgman joins the NiKang Board of Directors with over 20 years of experience in clinical development of oncology and hematology therapeutics.
  • “We are thrilled to welcome Dr. Borgman to our Board of Directors at this critical stage of NiKang,” said Zhenhai Gao, Ph.D., Co-founder, President and Chief Executive Officer of NiKang.
  • “As a highly accomplished executive, Dr. Borgman brings in much needed expertise in developing targeted oncology drugs to NiKang.

North America Cell-based Assays Market Report 2022: Featuring Becton, Dickinson, Bio-Rad Laboratories, Danaher, F. Hoffmann-La Roche & More - ResearchAndMarkets.com

Retrieved on: 
Friday, January 13, 2023

The "North America Cell-based Assays Market Size, Share & Industry Trends Analysis Report by Application (Drug Discovery, Basic Research and Others), End-user, Products & Services, Country and Growth Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "North America Cell-based Assays Market Size, Share & Industry Trends Analysis Report by Application (Drug Discovery, Basic Research and Others), End-user, Products & Services, Country and Growth Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering.
  • These assays include cell viability assays, cell proliferation assays, and GPCR assays.
  • These high-throughput assays speed up the process of drug discovery by giving the most promising candidate in the biological context that matters the most.
  • The US market dominated the North America Cell-based Assays Market by Country in 2021; thereby, achieving a market value of $7.2 billion by 2028.

Novo Nordisk announces FDA approval of label update for Rybelsus® (semaglutide) allowing use as a first-line option for adults with type 2 diabetes

Retrieved on: 
Friday, January 13, 2023

This update removes a previous limitation of use that stated the medication should not be used as the initial therapy for treating patients with type 2 diabetes.

Key Points: 
  • This update removes a previous limitation of use that stated the medication should not be used as the initial therapy for treating patients with type 2 diabetes.
  • "By taking Rybelsus® first, people with type 2 diabetes, in conjunction with their care teams, are now able to utilize this medicine early in their diabetes treatment journeys."
  • Novo Nordisk works with health insurance providers to ensure broad insurance coverage and patient access to Rybelsus®.
  • Eligible, commercially insured patients may pay as little as $10 for a one- to three-month prescription of this medicine.

Renowned Surgeons Publish Thyroid Nodule Size Chart During Thyroid Disease Awareness Month

Retrieved on: 
Thursday, January 12, 2023

TAMPA, Fla., Jan. 12, 2023 /PRNewswire/ -- January is Thyroid Disease Awareness Month, celebrated this year by the thyroid surgeons at the Hospital for Endocrine Surgery by publishing a new thyroid nodule size chart that lay-people can use to determine the significance of any thyroid nodule.

Key Points: 
  • TAMPA, Fla., Jan. 12, 2023 /PRNewswire/ -- January is Thyroid Disease Awareness Month, celebrated this year by the thyroid surgeons at the Hospital for Endocrine Surgery by publishing a new thyroid nodule size chart that lay-people can use to determine the significance of any thyroid nodule.
  • The incidence of having a thyroid nodule increases with age, with most adults over 50 having at least one thyroid nodule.
  • Thyroid nodules are the number one reason for thyroid surgery world-wide, with the need for surgery increasing as the nodule becomes bigger.
  • To produce the thyroid nodule size chart, thyroid surgeons reviewed data from the Center's past 10,000 thyroid surgeries to show the percent chance of needing surgery to remove all or part of the thyroid according to the size of the nodule.

Exelixis Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results, Provides 2023 Financial Guidance, and Outlines Key Priorities and Milestones for 2023

Retrieved on: 
Sunday, January 8, 2023

The preliminary 2022 financial information presented in this press release has not been audited and is subject to change.

Key Points: 
  • The preliminary 2022 financial information presented in this press release has not been audited and is subject to change.
  • The complete Exelixis Fourth Quarter and Full Year 2022 Financial Results are planned for release after market on Tuesday, February 7, 2023.
  • Exelixis President and Chief Executive Officer Michael M. Morrissey, Ph.D., will provide a corporate overview and discuss the company’s preliminary fourth quarter and full year 2022 financial results, 2023 financial guidance, and key priorities and milestones for 2023 during the company’s presentation at the J.P. Morgan Healthcare Conference beginning at 8:15 p.m.
  • To access the webcast link, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading.

Data Published in JCEM Demonstrate Strong Real-World Performance of Veracyte’s Afirma GSC in Thyroid Cancer Diagnosis

Retrieved on: 
Thursday, December 15, 2022

Veracyte, Inc. (Nasdaq: VCYT) today announced that findings demonstrating the strong real-world performance of the Afirma Genomic Sequencing Classifier (GSC) were published in The Journal of Clinical Endocrinology & Metabolism (JCEM) .

Key Points: 
  • Veracyte, Inc. (Nasdaq: VCYT) today announced that findings demonstrating the strong real-world performance of the Afirma Genomic Sequencing Classifier (GSC) were published in The Journal of Clinical Endocrinology & Metabolism (JCEM) .
  • Our analysis found that the test performs just as well and on some measures better in clinical practice.
  • This is incredibly encouraging and reassuring for physicians who must determine the best clinical approach for patients with indeterminate thyroid nodules.
  • The Afirma Genomic Sequencing Classifier helps physicians identify patients with benign thyroid nodules among those with indeterminate FNA results, so that they may avoid unnecessary thyroid surgery.

Bring Your Passion to Our Mission: More Than 20,000 Participants, Record Number of St. Jude Families to Run St. Jude Memphis Marathon Weekend

Retrieved on: 
Friday, December 2, 2022

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221202005080/en/
    St. Jude Memphis Marathon Weekend is the largest single day fundraiser for St. Jude Childrens Research Hospital.
  • Since its inception in 2002, St. Jude Memphis Marathon Weekend has grown into a celebration of community ties and relationships to St. Jude and Memphis that endure year after year.
  • Get full St. Jude Memphis Marathon Weekend details and donate to St. Jude at stjude.org/marathon .
  • Support the St. Jude mission by donating at stjude.org , liking St. Jude on Facebook , following St. Jude on Twitter , Instagram , LinkedIn and TikTok , and subscribing to its YouTube channel.

Pyxis Oncology Announces FDA Clearance of Two IND Applications

Retrieved on: 
Thursday, December 1, 2022

CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, announced today that it has received clearance for its two Investigational New Drug (IND) applications from the U.S. Food and Drug Administration (FDA) to initiate Phase 1 clinical trials. PYX-201, a novel antibody-drug conjugate (ADC) product candidate, will be investigated for the potential treatment of several solid tumors, including breast, head and neck, lung, and thyroid cancer. PYX-106, an immunotherapy product candidate, will be investigated for the potential treatment of solid tumors, including bladder, cholangio-carcinoma, colorectal, and kidney cancer.

Key Points: 
  • We are thrilled to receive two nearly simultaneous IND clearances from the FDA, representing a major moment as we transition to a clinical stage company demonstrating the operational prowess of our team, said Lara Sullivan, M.D., President and Chief Executive Officer of Pyxis Oncology.
  • Jay Feingold, M.D., Ph.D., Chief Medical Officer of Pyxis Oncology, added, "We are excited to advance multiple programs to the clinic.
  • Both product candidates could potentially be applied to a broad range of tumors and address a significant need in the community.
  • Pyxis Oncology, Inc. is a clinical stage company focused on defeating difficult-to-treat cancers.